Literature DB >> 33127595

Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts.

Lester Tsai1, Christopher Ma2, Parambir S Dulai1, Larry J Prokop3, Samuel Eisenstein4, Sonia L Ramamoorthy4, Brian G Feagan5, Vipul Jairath5, William J Sandborn1, Siddharth Singh6.   

Abstract

BACKGROUND & AIMS: We conducted a systematic review with meta-analysis to estimate rates and trends of colectomy in patients with ulcerative colitis (UC), and of primary and re-resection in patients with Crohn's disease (CD), focusing on contemporary risks.
METHODS: Through a systematic review until September 3, 2019, we identified population-based cohort studies that reported patient-level cumulative risk of surgery in patients with UC and CD. We evaluated overall and contemporary risk (after 2000) of surgery and analyzed time trends through mixed-effects meta-regression.
RESULTS: In patients with UC (26 studies), the overall 1-, 5-, and 10-year risks of colectomy was 4.0% (95% CI, 3.3-5.0), 8.8% (95% CI, 7.7-10.0), and 13.3% (95% CI, 11.3-15.5), respectively, with a decrease in risk over time (P < .001). Corresponding contemporary risks were 2.8% (95% CI, 2.0-3.9), 7.0% (95% CI, 5.7-8.6), and 9.6% (95% CI, 6.3-14.2), respectively. In patients with CD (22 studies), the overall 1-, 5-, and 10-year risk of surgery was 18.7% (95% CI, 15.0-23.0), 28.0% (95% CI, 24.0-32.4), and 39.5% (95% CI, 33.3-46.2), respectively, with a decrease in risk over time (P < .001). Corresponding contemporary risks were 12.3% (95% CI, 10.8-14.0), 18.0% (95% CI, 15.4-21.0), and 26.2% (95% CI, 23.4-29.4), respectively. In a meta-analysis of 8 studies in patients with CD with prior resection, the cumulative risk of a second resection at 5 and 10 years after the first resection was 17.7% (95% CI, 13.5-22.9) and 31.3% (95% CI, 24.1-39.6), respectively.
CONCLUSIONS: Patient-level risks of surgery have decreased significantly over time, with a 5-year cumulative risk of surgery of 7.0% in UC and 18.0% in CD in contemporary cohorts. This decrease may be related to early detection and/or better treatment.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Disease Modification; Inflammatory Bowel Diseases; Natural History; Resection; Tumor Necrosis Factor

Mesh:

Year:  2020        PMID: 33127595      PMCID: PMC8934200          DOI: 10.1016/j.cgh.2020.10.039

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  56 in total

1.  Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study.

Authors:  Marianne K Vester-Andersen; Ida Vind; Michelle V Prosberg; Bo G Bengtsson; Thomas Blixt; Pia Munkholm; Mikael Andersson; Tine Jess; Flemming Bendtsen
Journal:  J Crohns Colitis       Date:  2014-08-22       Impact factor: 9.071

Review 2.  Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.

Authors:  Alexandra D Frolkis; Jonathan Dykeman; María E Negrón; Jennifer Debruyn; Nathalie Jette; Kirsten M Fiest; Talia Frolkis; Herman W Barkema; Kevin P Rioux; Remo Panaccione; Subrata Ghosh; Samuel Wiebe; Gilaad G Kaplan
Journal:  Gastroenterology       Date:  2013-07-27       Impact factor: 22.682

3.  Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009.

Authors:  Anders Rönnblom; Tommy Holmström; Hans Tanghöj; Urban Karlbom; Mari Thörn; Daniel Sjöberg
Journal:  Scand J Gastroenterol       Date:  2016-06-29       Impact factor: 2.423

4.  Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort.

Authors:  E Langholz; P Munkholm; P A Krasilnikoff; V Binder
Journal:  Scand J Gastroenterol       Date:  1997-02       Impact factor: 2.423

5.  Postoperative health-care utilization in Crohn's disease: the impact of specialist care.

Authors:  Geoffrey C Nguyen; Fred Saibil; A Hillary Steinhart; Qi Li; Jill M Tinmouth
Journal:  Am J Gastroenterol       Date:  2012-07-31       Impact factor: 10.864

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Authors:  Jean-Frederic Colombel; Remo Panaccione; Peter Bossuyt; Milan Lukas; Filip Baert; Tomas Vaňásek; Ahmet Danalioglu; Gottfried Novacek; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; Walter Reinisch; William J Sandborn; Paul Rutgeerts; Daniel Hommes; Stefan Schreiber; Ezequiel Neimark; Bidan Huang; Qian Zhou; Paloma Mendez; Joel Petersson; Kori Wallace; Anne M Robinson; Roopal B Thakkar; Geert D'Haens
Journal:  Lancet       Date:  2017-10-31       Impact factor: 79.321

8.  Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study.

Authors:  Inger Camilla Solberg; Morten H Vatn; Ole Høie; Njaal Stray; Jostein Sauar; Jørgen Jahnsen; Bjørn Moum; Idar Lygren
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12       Impact factor: 11.382

9.  The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009.

Authors:  V Chhaya; S Saxena; E Cecil; S Chatu; V Subramanian; V Curcin; A Majeed; R C Pollok
Journal:  Aliment Pharmacol Ther       Date:  2014-11-10       Impact factor: 8.171

10.  Surgical Treatment in Childhood-onset Inflammatory Bowel Disease-A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014.

Authors:  Caroline Nordenvall; Oda Rosvall; Matteo Bottai; Åsa H Everhov; Petter Malmborg; Karin E Smedby; Anders Ekbom; Johan Askling; Jonas F Ludvigsson; Pär Myrelid; Ola Olén
Journal:  J Crohns Colitis       Date:  2018-01-24       Impact factor: 9.071

View more
  17 in total

Review 1.  Stopping Anti-TNF in CD Remitters: Cons.

Authors:  Taku Kobayashi
Journal:  Inflamm Intest Dis       Date:  2021-08-10

2.  Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study).

Authors:  Miki Miura; Hirotaka Shimizu; Daisuke Saito; Jun Miyoshi; Minoru Matsuura; Takahiro Kudo; Daisuke Hirayama; Masashi Yoshida; Katsuhiro Arai; Itaru Iwama; Hiroshi Nakase; Toshiaki Shimizu; Tadakazu Hisamatsu
Journal:  J Gastroenterol       Date:  2021-09-30       Impact factor: 7.527

3.  Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review.

Authors:  Nghia H Nguyen; Dominic Picetti; Parambir S Dulai; Vipul Jairath; William J Sandborn; Lucila Ohno-Machado; Peter L Chen; Siddharth Singh
Journal:  J Crohns Colitis       Date:  2022-03-14       Impact factor: 10.020

4.  Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.

Authors:  Rocio Sedano; Christopher Ma; Vipul Jairath; Brian G Feagan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-01

Review 5.  Ileal Pouch-Anal Anastomosis and Pouchitis: The Role of the Microbiota in the Pathogenesis and Therapy.

Authors:  Roberto Gabbiadini; Arianna Dal Buono; Carmen Correale; Antonino Spinelli; Alessandro Repici; Alessandro Armuzzi; Giulia Roda
Journal:  Nutrients       Date:  2022-06-24       Impact factor: 6.706

Review 6.  Prehabilitation prior to intestinal resection in Crohn's disease patients: An opinion review.

Authors:  Michiel T J Bak; Marit F E Ruiterkamp; Oddeke van Ruler; Marjo J E Campmans-Kuijpers; Bart C Bongers; Nico L U van Meeteren; C Janneke van der Woude; Laurents P S Stassen; Annemarie C de Vries
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

Review 7.  Manipulation of Gut Microbiota as a Key Target for Crohn's Disease.

Authors:  Reem Rashed; Rosica Valcheva; Levinus A Dieleman
Journal:  Front Med (Lausanne)       Date:  2022-06-16

8.  Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts.

Authors:  Lester Tsai; Jeffrey D McCurdy; Christopher Ma; Vipul Jairath; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2022-10-03       Impact factor: 7.290

9.  A Role for CXCR3 Ligands as Biomarkers of Post-Operative Crohn's Disease Recurrence.

Authors:  Margaret Walshe; Shadi Nayeri; Jiayi Ji; Cristian Hernandez-Rocha; Ksenija Sabic; Liangyuan Hu; Mamta Giri; Shikha Nayar; Steven Brant; Dermot P B McGovern; John D Rioux; Richard H Duerr; Judy H Cho; Phil L Schumm; Mark Lazarev; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2022-07-14       Impact factor: 10.020

10.  5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease.

Authors:  Vipul Yadav; Yang Mai; Laura E McCoubrey; Yasufumi Wada; Motoyasu Tomioka; Satofumi Kawata; Shrikant Charde; Abdul W Basit
Journal:  Biomedicines       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.